|
|
Reference
|
|
   3
|
Aaltonen, L.A., Peltomaki, P., Leach, F.S., Sistonen, P., Pylkkanen, L., Mecklin, J.P., Jarvinen, H., Powell, S.M., Jen, J., Hamilton, S.R. (1993) Clues to the pathogenesis of familial colorectal cancer. Science, 260(5109): 812-6
|
|
|
Ahnen, D.J., Feigl, P., Quan, G., Fenoglio-Preiser, C., Lovato, L.C., Bunn, P.A., Stemmerman, G., Wells, J.D., Macdonald, J.S., Meyskens, F.L. (1998) Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study. Cancer Res, 58(6): 1149-58
|
|
1
|
Allegra, C.J., Paik, S., Colangelo, L.H., Parr, A.L., Kirsch, I., Kim, G., Klein, P., Johnston, P.G., Wolmark, N., Wieand, H. (2003) Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol, 21(2): 241-50
|
|
|
Arnold, C.N., Goel, A., Boland, C. (2003) Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer, 106(1): 66-73
|
|
|
Aschele, C., Debernardis, D., Casazza, S., Antonelli, G., Tunesi, G., Baldo, C., Lionetto, R., Maley, F., Sobrero, A. (1999) Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol, 17(6): 1760-70
|
|
|
Bouzourene, H., Gervaz, P., Cerottini, J.P., Benhattar, J., Chaubert, P., Saraga, E., Pampallona, S., Bosman, F.T., Givel, J.C. (2000) p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer, 36(8): 1008-15
|
|
|
Bunz, F., Hwang, P.M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K.W., Vogelstein, B. (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest, 104(3): 263-9
|
|
|
Carethers, J.M., Hawn, M.T., Chauhan, D.P., Luce, M.C., Marra, G., Koi, M., Boland, C.R. (1996) Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine. J Clin Invest, 98(1): 199-206
|
|
|
Carethers, J.M., Chauhan, D.P., Fink, D., Nebel, S., Bresalier, R.S., Howell, S.B., Boland, C.R. (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology, 117(1): 123-31
|
|
|
Carethers, J.M., Smith, E., Behling, C.A., Nguyen, L., Tajima, A., Doctolero, R.T., Cabrera, B.L., Goel, A., Arnold, C.A., Miyai, K., Boland, C. (2004) Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology, 126(2): 394-401
|
|
|
Cascinu, S., Ligi, M., Graziano, F., del Ferro, E., Valentini, M., Grianti, C., Bartolucci, M., Catalano, G. (1998) S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma: Implications for adjuvant chemotherapy. Cancer, 83(6): 1081-5
|
|
4
|
Fearon, E.R., Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell, 61(5): 759-67
|
|
|
Gallego, M.G., Acenero, M.J., Ortega, S., Delgado, A.A., Cantero, J.L. (2000) Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum, 43(7): 971-5
|
|
|
Hawn, M.T., Umar, A., Carethers, J.M., Marra, G., Kunkel, T.A., Boland, C.R., Koi, M. (1995) Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res, 55(17): 3721-5
|
|
2
|
Herman, J.G., Umar, A., Polyak, K., Graff, J.R., Ahuja, N., Issa, J.P., Markowitz, S., Willson, J.K., Hamilton, S.R., Kinzler, K.W., Kane, M.F., Kolodner, R.D., Vogelstein, B., Kunkel, T.A., Baylin, S.B. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA, 95(12): 6870-5
|
|
4
|
Ionov, Y., Peinado, M.A., Malkhosyan, S., Shibata, D., Perucho, M. (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature, 363(6429): 558-61
|
|
|
Jackman, A.L., Kimbell, R., Ford, H.E. (1999) Combination of raltitrexed with other cytotoxic agents: Rationale and preclinical observations. Eur J Cancer, 35 Suppl 1: S3-8
|
|
|
Johnston, P.G., Benson, A.B., Catalano, P., Rao, M., O'Dwyer, P.J., Allegra, C.J. (2003) Thymidylate synthase protein expression in primary colorectal cancer: Lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol, 21(5): 815-9
|
|
|
Koi, M., Umar, A., Chauhan, D.P., Cherian, S.P., Carethers, J.M., Kunkel, T.A., Boland, C.R. (1994) Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res, 54(16): 4308-12
|
|
|
Kressner, U., Inganas, M., Byding, S., Blikstad, I., Pahlman, L., Glimelius, B., Lindmark, G. (1999) Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol, 17(2): 593-9
|
|
4
|
Lane, D.P. (1992) Cancer. p53, guardian of the genome. Nature, 358(6381): 15-6
|
|
|
Leichman, C.G., Lenz, H.J., Leichman, L., Danenberg, K., Baranda, J., Groshen, S., Boswell, W., Metzger, R., Tan, M., Danenberg, P.V. (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol, 15(10): 3223-9
|
|
|
Nehls, O., Klump, B., Holzmann, K., Lammering, G., Borchard, F., Gruenagel, H.H., Gaco, V., Gregor, M., Porschen, R. (1999) Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma. Cancer, 85(12): 2541-8
|
|
|
O'Connor, P.M., Jackman, J., Bae, I., Myers, T.G., Fan, S., Mutoh, M., Scudiero, D.A., Monks, A., Sausville, E.A., Weinstein, J.N., Friend, S., Fornace, A.J., Kohn, K.W. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res, 57(19): 4285-300
|
|
1
|
Ribic, C.M., Sargent, D.J., Moore, M.J., Thibodeau, S.N., French, A.J., Goldberg, R.M., Hamilton, S.R., Laurent-Puig, P., Gryfe, R., Shepherd, L.E., Tu, D., Redston, M., Gallinger, S. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med, 349(3): 247-57
|
|
|
Shih, C., Chen, V.J., Gossett, L.S., Gates, S.B., MacKellar, W.C., Habeck, L.L., Shackelford, K.A., Mendelsohn, L.G., Soose, D.J., Patel, V.F., Andis, S.L., Bewley, J.R., Rayl, E.A., Moroson, B.A., Beardsley, G.P., Kohler, W., Ratnam, M., Schultz, R.M. (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res, 57(6): 1116-23
|
|
|
Soong, R., Grieu, F., Robbins, P., Dix, B., Chen, D., Parsons, R., House, A., Iacopetta, B. (1997) p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res, 3(8): 1405-11
|
|
4
|
Thibodeau, S.N., Bren, G., Schaid, D. (1993) Microsatellite instability in cancer of the proximal colon. Science, 260(5109): 816-9
|
|
|
Veigl, M.L., Kasturi, L., Olechnowicz, J., Ma, A.H., Lutterbaugh, J.D., Periyasamy, S., Li, G.M., Drummond, J., Modrich, P.L., Sedwick, W.D., Markowitz, S.D. (1998) Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA, 95(15): 8698-702
|
|
|
Venkatesh, K.S., Weingart, D.J., Ramanujam, P.J. (1994) Comparison of double and single parameters in DNA analysis for staging and as a prognostic indicator in patients with colon and rectal carcinoma. Dis Colon Rectum, 37(11): 1142-7
|
|
|
Yamaguchi, A., Kurosaka, Y., Fushida, S., Kanno, M., Yonemura, Y., Miwa, K., Miyazaki, I. (1992) Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer, 70(12): 2778-84
|
|
|
|
|